Právní předpis byl sestaven k datu 25.12.2012.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. s., č. 46/2008 Sb. x. x. x č. 47/2012 Sb. x. x. x Mezinárodní xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 16. listopadu 2011 xxxx generální xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
S novým xxxxxx Přílohy X xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 odst. 3 Xxxxxx dne 1. xxxxx 2012 x tímto dnem xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx platné xx 1. xxxxx 2011 x vyhlášené xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx I x její překlad xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Xxxxx článku 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Zakázané xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx ze xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Zakázaných xxxxx X1, X2 x X3.
XXXXX X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx použití jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; mestanolon; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, ale xx x omezením xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), tibolon, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx skupiny xxxx xxxxx: * "xxxxxxxx" xx vztahuje x látce, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx produkovat přirozeně. ** "endogenní " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx produkovat xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx uvolňující faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Iuteinizační hormon (XX) x mužů;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový faktor (XXXX), stejně xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující xxxxxxx xxxx degradaci bílkovin xxxxx, xxxxx a xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx svalových xxxxxx;
x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
S3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx zakázáni xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx v xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 30 xx/xx nebude xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx užíváním xxxxxxxxxxxx inhalační xxxxx xxxxx než výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, formestan, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x omezením xxxxx xx xx.
3. Xxxxxxx antiestrogenní látky xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, ale ne x xxxxxxxx pouze xx xx.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. XX 1516) x Agonisté xxxxxxxxxxxxxxx xxx aktivované XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (např. XXXXX)
S5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx a xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx pro xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx použití (Xxx Soutěži, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx s xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum nebo xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Krevní xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, přenosu xxxx xxxxxxx kyslíku, xxxxxxxxxx xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx.xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), perfluorochemikálie x efaproxiral (RSR13), xxx xx x xxxxxxxx pouze xx xx. Dodávání kyslíku xxxxxxxx xxxx.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx zakázané. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více než 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, manipulace a xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve xx xxxxxxxxx xxxxxxx je xxxxxxxx.
X3. GENOVÝ XXXXXX
X důvodu xxxxxxxxxx ke zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx X5 a X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Soutěži zakázané x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx (xxxxxx obou xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx derivátů xxxxxxxxx x xxxxxxx jejich xxxxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, amfepramon, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), methylendioxyamfetamin, methylendioxymetamfetamin, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, katin***, efedrin****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, methylhexanamin (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx látky xxxxxxxx xx Monitorovacího xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx adrenalinu (xxxx. xxxxx, oční xxxxxxxx) xxxx xxxx xxxxxx společně x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx je zakázán, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx než 150 xxxxxxxxxx na mililitr
X7. NARKOTIKA
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. KANABINOIDY
Xxxxxxxx (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx delta9tetrahydrokanabinol (XXX) x kanabimimetika (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ a XX-210) jsou zakázané.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (FIA)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Lukostřelba (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx jinak xxxxxx, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Automobilový sport (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (XXX)
∙ Golf (IGF)
∙ Xxxxxxx a xxxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx také Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX)
∙ Střelba (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (WDF)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Acebutolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx ne s xxxxxxxx pouze xx xx.
Informace
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. byl xxxxxx xxxxxxx předpisem č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.